Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Perspective Therapeutics, Inc.CATX · Entity 694 | Chief Accounting Officer | March 02, 2026 | March 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Perspective Therapeutics, Inc.
Report date March 02, 2026 · Filed March 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.35 · Expires 2036-03-02 | Direct | 90,000 |
Reported balance
After 2026-03-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-02 · Grant · Acquired 90,000 · Balance 90,000 F1: The option grant was approved by the Compensation Committee of the Issuer's Board of Directors on February 4, 2026, with a grant date of March 2, 2026 (the "Grant Date"), and represents the Reporting Person's annual equity award for 2026. F2: Option vests and becomes exercisable over four years in 48 substantially equal monthly installments beginning on the date that is one month after the Grant Date, subject to the Reporting Person's continued service on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option grant was approved by the Compensation Committee of the Issuer's Board of Directors on February 4, 2026, with a grant date of March 2, 2026 (the "Grant Date"), and represents the Reporting Person's annual equity award for 2026.
F2: Option vests and becomes exercisable over four years in 48 substantially equal monthly installments beginning on the date that is one month after the Grant Date, subject to the Reporting Person's continued service on each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 02, 2026 Filed Mar 4, 2026 21:35 UTC | Perspective Therapeutics, Inc. CATX · Entity 694 | GrantStock option (right to buy) · Derivative | 90,000 | $0.00 Strike: $5.35 | $0.00 |
DisclosureSEC source: 0001375410-26-000003 · ownership.xml · derivative · entry 1 Hunt Jonathan Robert · CIK 0001375410 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2036-03-02 F1 · date: The option grant was approved by the Compensation Committee of the Issuer's Board of Directors on February 4, 2026, with a grant date of March 2, 2026 (the "Grant Date"), and represents the Reporting Person's annual equity award for 2026. F2 · derivative.exercise_date: Option vests and becomes exercisable over four years in 48 substantially equal monthly installments beginning on the date that is one month after the Grant Date, subject to the Reporting Person's continued service on each vesting date. Read SEC document |
| November 13, 2025 Filed Nov 17, 2025 13:01 UTC | Perspective Therapeutics, Inc. CATX · Entity 694 | PurchaseCommon Stock | 11,000 | $2.03 | $22,294.80 |
DisclosureSEC source: 0001193125-25-283953 · ownership.xml · nonDerivative · entry 1 Hunt Jonathan Robert · CIK 0001375410 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,800 F1 · price: The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.0235 to $2.0300, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price in the transactions described in this footnote. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:28 UTC | Perspective Therapeutics, Inc. CATX · Entity 694 | GrantStock option (right to buy) · Derivative | 75,000 | $0.00 Strike: $2.46 | $0.00 |
DisclosureSEC source: 0000950170-25-033665 · ownership.xml · derivative · entry 1 Hunt Jonathan Robert · CIK 0001375410 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2035-03-03 F1 · date: The option grant was approved by the Compensation Committee of the Issuer's Board of Directors on February 13, 2025, with a grant date of March 3, 2025 (the "Grant Date"), and represents the Reporting Person's annual equity award for 2025. F2 · derivative.exercise_date: Option vests and becomes exercisable over four years in 48 substantially equal monthly installments beginning on the date that is one month after the Grant Date, subject to the Reporting Person's continued service on each vesting date. Read SEC document |
| November 25, 2024 Filed Nov 27, 2024 12:00 UTC | Perspective Therapeutics, Inc. CATX · Entity 694 | PurchaseCommon Stock | 10,000 | $3.88 | $38,800.00 |
DisclosureSEC source: 0000950170-24-131250 · ownership.xml · nonDerivative · entry 4 Hunt Jonathan Robert · CIK 0001375410 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,800 Read SEC document |
| November 25, 2024 Filed Nov 27, 2024 12:00 UTC | Perspective Therapeutics, Inc. CATX · Entity 694 | PurchaseCommon Stock | 2,400 | $3.60 | $8,640.00 |
DisclosureSEC source: 0000950170-24-131250 · ownership.xml · nonDerivative · entry 3 Hunt Jonathan Robert · CIK 0001375410 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,800 Read SEC document |
| November 25, 2024 Filed Nov 27, 2024 12:00 UTC | Perspective Therapeutics, Inc. CATX · Entity 694 | PurchaseCommon Stock | 29 | $3.94 | $114.26 |
DisclosureSEC source: 0000950170-24-131250 · ownership.xml · nonDerivative · entry 2 Hunt Jonathan Robert · CIK 0001375410 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,400 Read SEC document |
| November 25, 2024 Filed Nov 27, 2024 12:00 UTC | Perspective Therapeutics, Inc. CATX · Entity 694 | PurchaseCommon Stock | 400 | $3.55 | $1,420.00 |
DisclosureSEC source: 0000950170-24-131250 · ownership.xml · nonDerivative · entry 1 Hunt Jonathan Robert · CIK 0001375410 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,371 Read SEC document |
| June 20, 2024 Filed Jun 24, 2024 20:05 UTC | Perspective Therapeutics, Inc. CATX · Entity 694 | GrantStock option (right to buy) · Derivative | 100,000 | $0.00 Strike: $10.65 | $0.00 |
DisclosureSEC source: 0000950170-24-076695 · ownership.xml · derivative · entry 1 Hunt Jonathan Robert · CIK 0001375410 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2034-06-20 F1 · derivative.exercise_date: Option vests over four years with 1/48th of the shares subject to such option vesting and becoming exercisable in substantially equal monthly installments on the monthly anniversary after the Grant Date (06/20/2024), subject to a continued service relationship. Read SEC document |
| June 17, 2024 Filed Jun 18, 2024 11:48 UTC | Perspective Therapeutics, Inc. CATX · Entity 694 | PurchaseCommon Stock | 1,800 | $9.82 | $17,667.00 |
DisclosureSEC source: 0000950170-24-074594 · ownership.xml · nonDerivative · entry 1 Hunt Jonathan Robert · CIK 0001375410 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,971 Read SEC document |
| May 31, 2024 Filed Jun 3, 2024 20:05 UTC | Perspective Therapeutics, Inc. CATX · Entity 694 | PurchaseCommon Stock | 12,000 | $1.40 | $16,800.00 |
DisclosureSEC source: 0000950170-24-067953 · ownership.xml · nonDerivative · entry 2 Hunt Jonathan Robert · CIK 0001375410 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 341,716 Read SEC document |
| May 31, 2024 Filed Jun 3, 2024 20:05 UTC | Perspective Therapeutics, Inc. CATX · Entity 694 | PurchaseCommon Stock | 13,006 | $1.40 | $18,207.10 |
DisclosureSEC source: 0000950170-24-067953 · ownership.xml · nonDerivative · entry 1 Hunt Jonathan Robert · CIK 0001375410 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 329,716 Read SEC document |
| December 18, 2023 Filed Dec 20, 2023 00:11 UTC | Perspective Therapeutics, Inc. CATX · Entity 694 | PurchaseCommon Stock | 125,000 | $0.26 | $32,337.50 |
DisclosureSEC source: 0001437749-23-034935 · rdgdoc.xml · nonDerivative · entry 1 Hunt Jonathan Robert · CIK 0001375410 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 316,710 Read SEC document |
| December 12, 2023 Filed Dec 14, 2023 23:36 UTC | Perspective Therapeutics, Inc. CATX · Entity 694 | GrantStock Options (right to buy) · Derivative | 1,248,776 | $0.00 Strike: $0.24 | $0.00 |
DisclosureSEC source: 0001437749-23-034477 · rdgdoc.xml · derivative · entry 1 Hunt Jonathan Robert · CIK 0001375410 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,527,429 Underlying: Common Stock · 1,248,776 shares Expires 2033-12-12 F1 · derivative.exercise_date: 25% vested as of 12/12/2023, and the remaining 75% will vest over the next three (3) years, commencing on 12/12/2024, until fully vested. Read SEC document |
| December 05, 2022 Filed Dec 5, 2022 23:09 UTC | Perspective Therapeutics, Inc. ISR · Entity 694 | PurchaseCommon Stock | 32,200 | $0.38 | $12,236.00 |
DisclosureSEC source: 0001437749-22-028455 · rdgdoc.xml · nonDerivative · entry 2 Hunt Jonathan Robert · CIK 0001375410 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,710 Read SEC document |
| December 01, 2022 Filed Dec 5, 2022 23:09 UTC | Perspective Therapeutics, Inc. ISR · Entity 694 | PurchaseCommon Stock | 53,204 | $0.38 | $20,265.40 |
DisclosureSEC source: 0001437749-22-028455 · rdgdoc.xml · nonDerivative · entry 1 Hunt Jonathan Robert · CIK 0001375410 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,510 Read SEC document |
| July 21, 2022 Filed Jul 29, 2022 01:04 UTC | Perspective Therapeutics, Inc. ISR · Entity 694 | GrantStock Options (right to buy) · Derivative | 475,000 | $0.00 Strike: $0.33 | $0.00 |
DisclosureSEC source: 0001437749-22-018051 · rdgdoc.xml · derivative · entry 1 Hunt Jonathan Robert · CIK 0001375410 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,278,653 Underlying: Common Stock · 475,000 shares Expires 2032-07-21 F1 · derivative.exercise_date: 25% vested as of 7/21/2022, and the remaining 75% will vest over the next three (3) years, commencing on 7/21/2023, until fully vested. Read SEC document |
| June 08, 2022 Filed Jun 9, 2022 21:18 UTC | Perspective Therapeutics, Inc. ISR · Entity 694 | PurchaseCommon Stock | 25,675 | $0.29 | $7,443.18 |
DisclosureSEC source: 0001437749-22-014695 · rdgdoc.xml · nonDerivative · entry 2 Hunt Jonathan Robert · CIK 0001375410 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,306 Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 21:18 UTC | Perspective Therapeutics, Inc. ISR · Entity 694 | PurchaseCommon Stock | 13,325 | $0.28 | $3,717.68 |
DisclosureSEC source: 0001437749-22-014695 · rdgdoc.xml · nonDerivative · entry 1 Hunt Jonathan Robert · CIK 0001375410 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,631 Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 20:25 UTC | Perspective Therapeutics, Inc. ISR · Entity 694 | GrantStock Options (right to buy) · Derivative | 320,000 | $0.00 Strike: $0.79 | $0.00 |
DisclosureSEC source: 0001437749-21-016448 · rdgdoc.xml · derivative · entry 1 Hunt Jonathan Robert · CIK 0001375410 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 803,653 Underlying: Common Stock · 320,000 shares Expires 2031-07-01 F1 · derivative.exercise_date: 25% vested as of 7/1/2021, and the remaining 75% will vest over the next three (3) years, commencing on 7/1/2022, until fully vested. Read SEC document |
| October 22, 2020 Filed Oct 28, 2020 20:43 UTC | Perspective Therapeutics, Inc. ISR · Entity 694 | PurchaseWarrant (right to buy) · Derivative | 33,653 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0001437749-20-021857 · rdgdoc.xml · derivative · entry 2 Hunt Jonathan Robert · CIK 0001375410 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 483,653 Underlying: Common Stock · 33,653 shares Expires 2025-10-22 F2 · shares: Purchased pursuant to public offering that closed on October 22, 2020. Each share of common stock purchased included one-half of a warrant. Each whole warrant is exercisable to purchase one share of common stock at an exercise price of $0.57 per share. Each warrant is immediately exercisable, and will expire October 22, 2025. F2 · derivative.exercise_date: Purchased pursuant to public offering that closed on October 22, 2020. Each share of common stock purchased included one-half of a warrant. Each whole warrant is exercisable to purchase one share of common stock at an exercise price of $0.57 per share. Each warrant is immediately exercisable, and will expire October 22, 2025. F2 · derivative.expiration_date: Purchased pursuant to public offering that closed on October 22, 2020. Each share of common stock purchased included one-half of a warrant. Each whole warrant is exercisable to purchase one share of common stock at an exercise price of $0.57 per share. Each warrant is immediately exercisable, and will expire October 22, 2025. Read SEC document |
| October 22, 2020 Filed Oct 28, 2020 20:43 UTC | Perspective Therapeutics, Inc. ISR · Entity 694 | PurchaseCommon Stock | 67,306 | $0.52 | $34,999.12 |
DisclosureSEC source: 0001437749-20-021857 · rdgdoc.xml · nonDerivative · entry 1 Hunt Jonathan Robert · CIK 0001375410 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,306 F1 · shares: Purchased pursuant to public offering that closed on October 22, 2020. F1 · price: Purchased pursuant to public offering that closed on October 22, 2020. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 20:38 UTC | Perspective Therapeutics, Inc. ISR · Entity 694 | GrantStock Options (right to buy) · Derivative | 150,000 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001437749-20-013870 · rdgdoc.xml · derivative · entry 1 Hunt Jonathan Robert · CIK 0001375410 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,000 Underlying: Common Stock · 150,000 shares Expires 2030-06-23 F1 · derivative.exercise_date: 25% vested as of 6/23/2020, and the remaining 75% will vest over the next three (3) years, commencing on 6/23/2021, until fully vested. Read SEC document |
| June 18, 2019 Filed Sep 4, 2019 22:48 UTC | Perspective Therapeutics, Inc. ISR · Entity 694 | GrantStock Options (right to buy) · Derivative | 150,000 | $0.00 Strike: $0.43 | $0.00 |
DisclosureSEC source: 0001437749-19-017904 · rdgdoc.xml · derivative · entry 1 Hunt Jonathan Robert · CIK 0001375410 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 150,000 shares Expires 2029-06-18 F1 · derivative.exercise_date: 25% vested as of 6/18/2019, and the remaining 75% will vest over the next three (3) years, commencing on 6/18/2020, until fully vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.